Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 18, 2026

Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%?

View original at finance.yahoo.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? Daniel J. Englander, Director at Copart, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Daniel J. Englander sold 80,000 shares of Copart common stock on July 13, 2026, for a transaction value of $2.2 million.

    60% confidence
  • Daniel J. Englander holds no shares directly; his remaining interest consists of approximately 511,000 shares held indirectly through Ursula Capital Partners, representing a 0.0552% ownership stake in Copart.

    60% confidence
  • Copart operates as a global provider of online vehicle auctions with a market capitalization of $25.5 billion as of the July 14, 2026 market close, generating $4.6 billion in trailing twelve-month revenue and $1.6 billion in net income over the same period.

    60% confidence
  • The shares were sold in multiple transactions at prices ranging from $27.50 to $27.66, with the reported price of $27.55 reflecting the weighted average of these executions.

    60% confidence
  • Ursula Capital Partners distributed 40,000 shares to its limited partners on July 13, 2026, and Daniel J. Englander was excluded from this distribution.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? — Source | Via News | ViaNews Market